Brief: Ascelia Pharma's Orviglance Data Shows Sparkle Study Can Be Completed With Fewer Patients

Ascelia Pharma AB

06/12/2022 07:08

Dec 6 (Reuters) - Ascelia Pharma AB  ACELP.ST :
    * NEW DATA SHOW THAT PIVOTAL PHASE 3 CLINICAL SPARKLE STUDY
WITH
ORVIGLANCE CAN BE COMPLETED WITH 80 PATIENTS
    * COMPLETE PATIENT ENROLLMENT EXPECTED IN FEB-MAR 2023,
SUBSEQUENT
TOPLINE READOUT BY MID-2023

Source text for Eikon:  ID:nMFN1Stz4S 
Further company coverage:  ACELP.ST 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))